Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-26T05:25:51.647Z Has data issue: false hasContentIssue false
  • English
  • Français

Foreword — Global Access to Health: Legal, Business, and Policy Obstacles

Published online by Cambridge University Press:  06 January 2021

Erik Iverson  and
Regina Rabinovich
Erik Iverson
Affiliation:
Bill & Melinda Gates Foundation
Regina Rabinovich
Affiliation:
Infectious Diseases, Global Health Program, Bill & Melinda Gates Foundation
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Foreword
Information
American Journal of Law & Medicine , Volume 34 , Issue 2-3 , June 2008 , pp. 97 - 106
Copyright
Copyright © American Society of Law, Medicine and Ethics and Boston University 2008

References

1 Jeffrey H. Matsura, Thomas Jefferson and the Evolution of a Populist Vision of Intellectual Property Rights and Democratic Values, http://www.archipelago.org/vol10-34/matsuura.htm.

2 Thomas Jefferson, The Papers of Thomas Jefferson 1 January 1794 to 29 February 1796 (Princeton University Press 2000).

3 World Health Organization, The World Health Report 1998, Chapter 8, http://www.who.int/entity/whr/1998/en/whr98_ch8.pdf.

4 Jamison, Dean T., et al., Accomplishments, Challenges, and Priorities, Priorities in Health, 1, 1–22 (Oxford University Press 2006)CrossRefGoogle Scholar.

5 World Health Organization, e (revised January 2007), http://www.who.int/mediacentre/factsheets/fs286/en/index.html.

6 World Health Organization, Global Immunization Data (January 2008), http://www.who.int/immunization/newsroom/Global_Immunization_Data.pdf.

7 Jamison, Dean T., et al., The Way Forward: A Blueprint for Action, Priorities in Health 179-82 (Oxford University Press 2006)Google Scholar.

8 The Global Fund, http://www.theglobalfund.org.

9 U.S. Census Bureau, 2006 estimates, http://www.census.gov.

10 Planning Report 07-1, Economic Analysis of the Technology Infrastructure Needs of the U.S. Biopharmaceutical Industry, RTI International, Nov. 2007 (prepared for National Institute of Standards & Technology) (biopharma firms spend some $21 billion a year on research and development).

11 Global Framework on Essential Health R&D, 367 The Lancet 1560 (2006). Although there are many ways of defining “Developing Countries,” the World Bank's categorization of “low-income economies” or “lower middle-income economies” are often referenced. Depending on the context and the parties offering a definition, such term might also include certain markets or countries within the categorization of “upper middle-income economies.”

12 Medicines for Malaria Venture, http://www.mmv.org ; TB Alliance, http://www.tballiance.org.

13 The Aeras Global TB Vaccine Foundation, http://www.aeras.org.

14 See The GAVI Alliance, http://www.gavialliance.org , for GAVI, IFFm, and ADIPs; see The Center for Global Development, Making Markets for Vaccines, http://www.cgdev.org/section/initiatives/_active/vaccinedevelopment , for AMCs.

15 Jefferson, Thomas: A Chronology of His Thoughts (Holmes, Jerry, ed. 2002)Google Scholar.